🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yaël P. Mossé

Children's Hospital of Philadelphia

ORCID: 0000-0002-3463-0399

Also affiliated with University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.”.

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10500
N/A
0DataRank · unranked
4 citations

Meaghan Granger, Susan Groshen, Denice Tsao‐Wei, Anasheh Shamirian, Scarlett Czarnecki +15 more

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

UNC Libraries(2020)10.17615/dawp-6r12
N/A
0DataRank · unranked
0 citations

Yaël P. Mossé, Patrick A. Thompson, Frank M. Balis, Elizabeth Fox, Susan M. Blaney +2 more

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.006
N/A
0DataRank · unranked
33 citations

Arlene Naranjo, Rochelle Bagatell, Steven G. DuBois, Jeannine S. McCune, Sheena C. Tenney +17 more

Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10037
N/A
0DataRank · unranked
9 citations

Yaël P. Mossé, Vanessa Del Pozo, Eric J. Earley, Stephen W. Erickson, David Groff +9 more

Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10041
N/A
0DataRank · unranked
0 citations

Yaël P. Mossé, Kimberly Kayser, Yueh‐Yun Chi, Marc Chioda, Holger Thurm +14 more

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.06.570390
N/A
0DataRank · unranked
5 citations

Alexander B. Radaoui, Matthew Tsang, Daniel Martínez, Simone Sidoli, Karina L. Conkrite +31 more

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

Cancer Cell(2024)10.1016/j.ccell.2024.10.003
N/A
0DataRank · unranked
18 citations

Alexander B. Radaoui, Matthew Tsang, Daniel Martínez, Karina L. Conkrite, Khushbu Patel +33 more

Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models

Scientific Reports(2024)10.1038/s41598-024-69382-8
N/A
0DataRank · unranked
1 citations

Licai Huang, Zhongting Zhang, Zhenlin Ju, Xingzhi Song, E. Anders Kolb +14 more

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.06.27.600865
N/A
0DataRank · unranked
2 citations

Michal Odrobina, Nathaniel W. Mabe, Alvin Farrel, Liron D. Grossmann, Matthew Tsang +9 more

Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets

Neuro-Oncology(2025)10.1093/neuonc/noaf012
N/A
0DataRank · unranked
7 citations

Michal Odrobina, Nathaniel W. Mabe, Alvin Farrel, Liron D. Grossmann, Matthew Tsang +10 more

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0684
N/A
0DataRank · unranked
4 citations

Michael P. East, Timothy J. Stuhlmiller, Gabriela M. Witek, Alvin Farrel, Steven Pastor +13 more

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Nature Communications(2025)10.1038/s41467-025-62979-1
N/A
0DataRank · unranked
4 citations

Smita Matkar, Christina Acholla, Colleen E. Casey, Grant Li, Martina Mazzeschi +28 more

Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma.

UNC Libraries(2025)10.17615/pbz0-mn14
N/A
0DataRank · unranked
0 citations

Mark Gerelus, Michael P. East, Alvin Farrel, Steven Pastor, John M. Maris +13 more